Xeloda
Xeloda is the brand name for capecitabine, an oral chemotherapy drug used to treat several cancers. It is a prodrug of the anticancer agent 5-fluorouracil (5-FU) and is designed to be converted to 5-FU mainly within tumor tissue, allowing targeted cytotoxic effects while aiming to limit systemic exposure.
Mechanism of action involves conversion of capecitabine to 5-FU, which inhibits thymidylate synthase and disrupts RNA
Indications include colorectal cancer (both adjuvant and metastatic settings) and metastatic breast cancer, with use in
Administration and dosing are oral and typically involve taking capecitabine twice daily for 14 days, followed
Adverse effects most commonly include hand-foot syndrome (palmar-plantar erythrodysesthesia), diarrhea, mucositis, nausea, vomiting, fatigue, rash, and